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Summary. We evaluated the effect of trimetazidine (TMZ) 
on recovery of regional cardiac function in anesthetized 
open-chest pigs, subjected to fifteen 2-minute occlusions of 
the left anterior descending coronary artery, separated by 
2 minutes of reperfusion and a 120-minute recovery period. 
Regional myocardial function was evaluated by sonomi- 
crometry-derived segment lengthening and the area enclosed 
by the left ventricular pressure-segment length loop (external 
work, EW) in animals, which received either an intracoro- 
nary infusion of TMZ (33 ~tg/kg/min, n = 6) or saline (1 ml/ 
min, n = 7), starting 15 minutes before the first occlusion 
and ending 2 minutes after the 15th occlusion. In addition, 
myocardial malondialdehyde production to evaluate oxygen 
free radical production, oxygen consumption, and the ATP, 
ADP, and AMP content, as well as the energy charge, were 
determined at regular time intervals. 
In control pigs the sequences of occlusion-reperfusion did
not affect systemic hemodynamics, except for the LVdP/ 
dtm~ x, which decreased by 11% during the interventions and 
did not recover during the following reperfusion period of 2 
hours (78% of baseline, p < 0.05). Systolic segment length 
shortening and EW were increased at the end of the first 
ocelusion-reperfusion cycle, decreased gradually during the 
remainder of the ocelusion-reperfusion periods, and did not 
improve during the recovery period. Energy charge and myo- 
cardial blood flow were not impaired, but oxygen consump- 
tion was decreased uring the recovery period. The malondi- 
aldeyde data did not provide evidence for production of 
oxygen free radicals. TMZ decreased LVdP/dt~ by 6% (p < 
0.05) and caused a twofold increase in postsystolic segment 
shortening (p < 0.05) before the first occlusion, but did not 
influence the hemodynamic responses, the changes in re- 
gional cardiac function, and the metabolic events produced 
by repetitive regional ischemia. 
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The effectiveness of the l-(2,3,4-trimethoxybenzyl)- 
piperazine dihydrochloride, trimetazidine, in increas- 
ing the ischemic threshold uring exercise tolerance 
testing without obvious changes in hemodynamic pa- 
rameters has led to further investigations concerning 
the mechanisms by which the drug exerts its action 
[1-3]. A number of properties, mainly demonstrated 
in isolated organs and tissues, have been identified 
that could explain the cardioprotective activity of tri- 
metazidine: (a) reduced intracellular acidosis during 
ischemia [4,5], (b) accelerated adenine nucleotide 
rephosphorylation [4,6], (c) decreased membrane con- 
tent of peroxidized lipids [7], and (d) diminished cellu- 
lar edema nd preservation ofoxidative phosphoryla- 
tion during reperfusion. The latter two arguments 
indicate a reduction in oxygen free radical production 
[8]. 
Kober et al. [9] demonstrated recently that intra- 
coronary administration of trimetazidine delayed the 
development and reduced the magnitude of ECG 
changes in patients undergoing percutaneous translu- 
minal coronary angioplasty (PTCA) during balloon in- 
flation. In this study it was not investigated whether 
this was also accompanied by an improved recovery 
of regional cardiac function after reperfusion was rein- 
stated. Several studies uggest that, in particular, the 
diastolic function shows an impaired recovery after 
repeated brief (2-4 minute) coronary artery occlu- 
sions [10,11]. 
In the present study we, therefore, investigated 
the effects of trimetazidine on the recovery of regional 
cardiac function after multiple 2-minute occlusions 
separated by 2 minutes of reperfusion, mimicking a 
clinical PTCA protocol. Since other studies [7,8] have 
indicated that trimetazidine or its metabolite(s) may 
reduce the formation of oxygen free radicals, a poten- 
tial mechanism for myocardial stunning [12], we also 
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determined myocardial malondialdehyde (MDA) pro- 
duction to investigate whether the formation of oxy- 
gen free radicals plays a role in this model. 
Methods  
Surgical procedure 
After an overnight fast, crossbred Landrace × York- 
shire pigs of either sex (25-32 kg) were sedated with 
25 mg/kg ketamine (A.U.V., Cuijck, The Nether- 
lands) i.m., anesthetized with 18 mg/kg pentobarbital 
(Sanofi, Paris, France) i.v., intubated, and connected 
to a respirator for intermittent positive pressure ven- 
tilation with a mixture of oxygen and nitrogen. By 
adjusting respiratory rate, tidal volume, and the frac- 
tion of oxygen in the inspired mixture, arterial blood 
gases and pH were kept within the normal limits. The 
temperature of the animal was kept around 37°C by 
using an electrical blanket. Anesthesia was main- 
tained with a continuous infusion of pentobarbital 
(10-15 mg/kg/h, i.v.). Saline and haemaccel (Behring- 
werke A.G., Marburg, Germany) were infused to 
maintain the fluid balance via catheters inserted into 
the external jugular vein. Catheters were also posi- 
tioned via both femoral arteries into the descending 
aorta for measurement of central aortic blood pres- 
sure and withdrawal of blood samples for determina- 
tion of blood gases and malondialdehyde concentra- 
tions. A 7F Sensodyn microtransducer catheter (B. 
Braun Medical B.V., Uden, The Netherlands) was ad- 
vanced into the left ventricle (LV) via the carotid ar- 
tery to monitor left ventricular pressure and its first 
derivative (LVdP/dt). Following administration f 4 
mg pancuronium bromide (Organon Teknika B.V., 
Boxtel, The Netherlands) i.v., a midline thoracotomy 
was performed, the left mammary vessels were li- 
gated, and the second and third left ribs were partly 
removed to facilitate additional instrumentation. An
electromagnetic flow probe (Skalar, Delft, The Neth- 
erlands) was placed around the ascending aorta and 
the left atrial appendage was cannulated for injection 
of 1-2 x 108 microspheres, 15_+ 1 (SD) ~m in diame- 
ter (NEN Company, Dreieich, Germany), labelled 
with either 95NB, l°~Ru, n3Sn, 46Sc, or 141Ce, to deter- 
mine regional myocardial blood flow using the refer- 
ence blood sample technique. For the measurement of 
regional segment shortening by sonomicrometry (Tri- 
ton Technology, San Diego, CA) ultrasonic rystals 
(Sonotek Corporation, Del Mar, CA) were positioned 
in the layers of the left ventricle subendocardium, coy- 
ering the interventional area as well as a control area. 
The proximal left anterior descending coronary artery 
(LADCA) was dissected free to apply intermittent oc- 
clusions with an atraumatic clamp and a proximally 
placed electromagnetic flow probe. Distal to this site 
a small cannula (0.8 mm outer diameter) was inserted 
into the LADCA for the administration f either tri- 
metazidine or saline. The vein accompanying the 
LADCA was cannulated for the determination f coro- 
nary venous blood gases, malondialdehyde, and hemo- 
globin concentrations. At the end of the experiment 
the interventional area was identified by an intraatrial 
injection of methylene blue after the LADCA had 
been occluded again. The pigs were then sacrificed 
with an overdose of pentobarbital, nd the heart was 
excised and processed to determine regional myocar- 
dial blood flow. 
Experimental procedure and data analysis 
After surgical preparation the pigs were allowed to 
stabilize for 45 minutes. Prior to the intervention pro- 
tocol, which consisted of 15 sequences of 2-minute 
occlusion and 2 minutes reperfusion, pigs either 
received an intracoronary infusion of saline or trimet- 
azidine (33 ~Lg/kg/min) at a rate of 1 ml/min, which 
started 15 minutes before the first occlusion and con- 
tinued until the end of reperfusion 15 (at 2 minutes of 
the final reperfusion period), which was then followed 
by 2 hours of recovery. At scheduled intervals record- 
ings were made of systemic hemodynamic variables 
and regional myocardial function, arterial and coro- 
nary venous blood samples were drawn to quantify 
oxygen consumption a d malondialdehyde production, 
biopsies were taken for the determination of high- 
energy phosphates, and microspheres were injected 
to obtain regional blood flow data. 
From the segment length tracings were calculated 
(Figure 1) (a) regional systolic segment shortening as 
SS(%) = 100 x (EDL - ESL)/EDL, in which EDL 
and ESL are the segment length at end diastole and 
end systole, respectively; (b) regional postsystolic 
segment shortening (PSS) as PSS(%) = 100(%) x 
(ESL - minL)/EDL, in which minL is the segment 
length at maximal contraction; (c) normalized regional 
velocity of contraction (Vc) as Vc(mm/s) = 10(ram) 
(EDL-ESL/EDL)/tsystole, inwhich tsy~tole equals the du- 
ration of left ventricular ejection; and (d) the relax- 
ation time (ts0) as the duration of the period (ms) in 
which 50% of total segment lengthening was achieved. 
Left ventricular pressure and myocardial segment 
length were digitized (sample rate 250 Hz) using an 
8-bit AD converter (Tiepie Engineering, Leeuwar- 
den, The Netherlands) on an IBM PC computer to 
calculate the area enclosed by the pressure-segment 
length loop over a full cardiac ycle [13], which is an 
index of regional myocardial work [14]. 
High-energy phosphates were measured in 
transmural myocardial biopsies, taken with a Tru-Cut 
needle (Travenol Laboratories, Deerfield, IL) from 
the intermittent ischemic area and the adjacent con- 
trol area. Biopsies were immediately dipped into 0.9% 
NaC1 at 0°C to remove adherent blood, frozen in liquid 
nitrogen (within 10 seconds), and stored until analysis 
at -80°C [15]. 
MDA formation was measured in blood samples 
that were placed on ice directly after sampling, centri- 
fuged at 0°C to obtain plasma, and stored at -80°C 
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Fig. 1. Calculation of regional segment funct ion data f~vm the segment length tracings. AoP = aortic pressure; LVP  = left ven- 
tricular pressure; LVdPdt  x f irst derivative of LVP;  SL = segment length; EDL  = end-diastolic length; ESL  = end-systolic 
length; minL  = min imum length (at max imal  contraction); 50%L = length at 50% relaxation; tsysto~ e = duration of left ventricu- 
lar eiection; tso = time-pe,'iod in which 50% of the relaxation is achieved. 
until analysis. The MDA content of the plasma sam- 
ples was measured as previously described [16]. 
Oxygen consumption (MVQ) and MDA production 
were calculated as the product of regional transmural 
myocardial blood flow and the difference in the arte- 
rial and coronary venous contents. Energy charge was 
calculated as (ATP + 0.5 ADP)/[ATP + ADP + 
AMP] as defined by Atkinson [17]. 
Statistical analysis 
All data are presented as mean _+ SEM. Statistical 
analysis was performed by use of a parametric two- 
way analysis of variance (randomized block design), 
followed by the Duncan new multiple range test. Sta- 
tistical significance was accepted at p < 0.05 (two- 
tailed). 
Drugs 
Except for the anesthetic drugs, only trimetazidine 
(courtesy of Dr. C. Harpey, I.R.I.S., Courbevoie, 
France) dissolved in isotonic saline was used. 
Results 
Systemic hemodynamics 
Two minutes after the last occlusion, LVdP/dtm~ x had 
decreased to 85-90% of the preocclusion value, but 
none of the other cardiovascular variables were sig- 
nificantly affected (Table 1). During the following 15 
minutes, there was an additional decrease in LVdP/ 
dtma x to 80% of its preocclusion value (p < 0.05), not 
followed by any sign of recovery. Hence, at the end 
of the recovery period, the values of all variables ex- 
cept for that of LVdP/dtma x were similar to those ob- 
served before the first occlusion. 
Infusion of trimetazidine did not alter heart rate, 
mean arterial blood pressure, cardiac output, and left 
ventrieular end-diastolic pressure, but decreased 
LVdP/dtma x by 6% (p < 0.05). The drug did not modify 
the changes in the hemodynamie variables during the 
ocetusion-reperfusion protocol. During the recovery 
period, in contrast with the untreated animals, there 
was a complete recovery of LVdP/dtma x in the trimeta- 
zidine-treated animals (Table 1). 
Regional myocardial wall function 
In the untreated animals, the first occlusion caused a 
complete loss of systolic segznent shortening (SS) of 
the myocardium perfused by the LADCA, but there 
was a complete recovery during reperfusion (Figure 
2). As a matter of fact SS was even slightly increased 
to above baseline. During the subsequent occlusion- 
reperfusion cycles there was again a complete loss of 
function during occlusion, while recovery became only 
partial during reperfusion. Consequently, 2 minutes 
after the 15th occlusion SS had decreased from 18 _+ 
2% at baseline to 13 _+ 2% (p < 0.05) and further 
declined to 9 _+ 1% (p < 0.05) during the following 15 
minutes. There were no further changes in SS during 
the remainder of the reperfusion period. Postsystolic 
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Table 1. Systemic hemodynamic effects induced by 15 consecutive cycles of 2 minutes occlusion and 2 minutes reperfusion in 
untreated (C, n = 7) and trimetazidine-treated (TMZ, n = 6) open-chest anesthetized pigs 
Recovery after last occlusion (minutes) 
Pretr imetazidine Preocclusion 2 15 60 120 
HR C 111 _+ 7 112 _+ 7 109 -+ 5 108 _+ 6 108 _+ 7 111 -+ 8 
TMZ 105 -+ 7 104 +_ 8 106 _+ 6 106 ± 5 108 -+ 5 104 ± 6 
MAP C 97 _+ 4 98 ± 3 94 ± 5 93 ± 6 91 _+ 2 98 -+ 6 
TMZ 91 ± 3 92 ± 3 85 ± 2 84 ± 2 b 82 ± 2 a,b 83 ± 5 
LVdP/dtmax C 2180 ± 190 2360 ± 160 2070 -+ 110 1850 -- 170 ~ 1840 ± 180 a 1890 ± 210 a 
TMZ 2250 ±- 250 2090 ± 210 ~ 1950 ± 210 1880 ± 230 ~ 2000 ± 310 2480 z 300 
LVEDP C 14 ± t 14 ± 1 14 -+ i 14 ± 1 13 ± 1 13 ± 1 
TMZ 12 ± 2 13 ± 2 14 ± 2 t4 ± 2 14 _+ 2 12 _~ 2 
CO C 2.6 ± 0.3 2.6 ± 0.2 2.5 ± 0.2 2.5 ± 0.2 2.4 ± 0.3 2.3 _+ 0.2 
TMZ 2.3 +- 0.2 2.5 ± 0.3 2.5 ± 0.2 2.5 ± 0.2 2.4 ± 0.2 2.2 ± 0.3 
SVR C 40_+ 3 40 ± 4 39 ± 3 38 ± 3 44 ± 5 46 ± 6 
TMZ 40 +- 3 38 ± 4 35 ± 2 34 ± 2 36 ± 3 39-+ 4 
Trimetazidine infusion (33 ~g/kg/bin) started 15 minutes prior to the first occlusion and lasted until 2 minutes after the last occlusion. 
HR = heart rate (beats/min); MAP = mean arterial blood pressure (mbHg); LVdP/dtm,x = maximal rate of rise of left ventricular pressure 
(mmHg/s); LVEDP = left ventricular end-diastolic pressure (bmHg); CO = cardiac output (1/bin); SVR = systemic vascular esistance 
(mmHg/min/1). 
Data have been expressed as bean -+ SEM. 
ap < 0.05 versus baseline; bp < 0.05 versus tribetazidine. 
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Fig. 2. Effect of 15 consecutive occlusion-reperfusion periods of 2 minutes each in untreated (open columns, n = 7) and 
trimetazidine-treated (hatched columns, n = 6) animals on segment length changes (SS), postsystolic segment length changes 
(PSS), velocity of contraction (Vc), and relaxation time (tso). Data are shown from 15 and 0 minutes before the first occlusion and 
from the end of the 1st (1), 5th (5), lOth (10), and 15th (15) occlusion-reperfusion periods and from 15 (15), 60 (60), and 120 
minutes of reperfusion during the recovery period. Trimetazidine was administrated before and during the occlusion-reperfusion 
periods. *p < 0.05 versus minus 15 minutes (-15) before the first occlusion. Data are presented as mean ± standard e~ror of the 
mean.  
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shortening (PSS) was absent at baseline and also after 
the first occlusion-reperfusion sequence, but gradually 
increased uring the following occlusion-reperfusion 
sequences (4 ± 1% after the 15th sequence). There 
were no further changes in PSS during the recovery 
period. The changes in the velocity of systolic shorten- 
ing were parallel to those in SS, because heart rate 
and the duration of systole did not change. The relax- 
ation time was not affected by the first occlusion- 
reperfusion sequence, but gradually shortened uring 
the following sequences, to be prolonged again during 
the 120-minute recovery period. In the adjacent con- 
trol region SS decreased from 17 ± 1% at baseline to 
13 ± 1% 2 minutes after the last occlusion period and 
did not change during the ensuing recovery period of 
120 minutes. PSS never became significantly different 
from zero, and the changes in the velocity of shorten- 
ing again paralleled those in SS, while relaxation time 
was not affected. 
Intracoronary infusion of trimetazidine had no sig- 
nificant effect on SS, neither before and during the 
occlusion-reperfusion periods, nor during the 120- 
minute recovery period (Figure 2). The same was true 
for velocity of shortening and the relaxation time. 
PSS, however, increased from 1 ± 0.3% to 4 ± 0.4% 
(p < 0.05), which was neither enhanced by the repeti- 
tive occlusions nor attenuated uring the recovery 
period. 
External work 
In the untreated animals, the index reflecting the ex- 
ternal work performed by the myocardium perfused 
by the LADCA (231 ~ 31 mmHg/mm at baseline) 
decreased to virtually zero during the occlusions, but 
was unchanged at the end of the 1st, 5th, 10th, and 
15th reperfusions. During the following 120-minute 
recovery period there was a decline to 151 ± 18 
mmHg/mm (p < 0.05) after 15 minutes, which did 
not improve during the remainder of the observation 
period (140 ± 16 mmHg/mm after 120 minutes). 
Trimetazidine administration tended to decrease 
external work in the intervention region (231 ± 33 
mmHg/mm at baseline and 217 ± 8 mmHg/mm after 
10-minute intracoronary infusion, p = 0.16). During 
the following occlusion-reperfusion sequences, th  
changes in the trimetazidine animals resembled 
closely those in the untreated animals (199 ± 38 
mmHg/mm after the last occlusion-reperfusion cycle 
and 178 ± 36 mmHg/mm after 120 minutes of re- 
covery). 
Myocardial blood flow 
Baseline values of the untreated animals and the tri- 
metazidine-treated animals of the myocardium per- 
fused by the LADCA were very similar (158 ± 13 ml/ 
min/100 g and 160 ± 18 ml/min/100 g, respectively). 
In either group of animals, transmural blood flow and 
its distribution over the subendocardial nd subepi- 
cardial layers were not different from baseline, both 
at 15 and 60 minutes of the recovery period (not 
shown). There were also no changes in the perfusion 
of the myocardium outside the distribution area of the 
LADCA (not shown). 
Oxygen consumption of the myocardium 
perfused by the left anterior descending 
coronary artery 
Fifteen minutes after the last of 15 sequences ofocclu- 
sion and reperfusion, myocardial oxygen consumption 
(MVQ) of the LADCA-perfused myocardium was re- 
duced from 486 ± 31 ~Lmol/min/g to 326 -+ 44 ~LmO1/ 
min/g (p < 0.05) and did not fully recover during the 
following 60 minutes of reperfusion (394 ± 20 ~LmO1/ 
rain/g, p < 0.05). Trimetazidine did not modify this 
pattern, as MVO 2 had decreased from 467 ± 48 ~Lmol/ 
min/g to 362 ± 86 ixmol/min/g (p < 0.05) at 15 min- 
utes of reperfusion in the treated animals and was 
only 372 ± 27 jxmol/min/g after 60 minutes of reper- 
fusion. 
Myocardial high-energy phosphate levels 
In the untreated animals, myocardial ATP content 
after the first five occlusion-reperfusion sequences (28 
± 2 ~Lmo1/g protein) was not different from the values 
measured at baseline (28 ± 3 ~gmol/g protein), but 
during the following 10 occlusion-reperfusion se- 
quences there was a gradual decrease to 23 ± 2 ~Lmol/ 
g protein (p < 0.05). There was no recovery during 
the first 15 minutes of reperfusion (20 ± 2 ~mol/g 
protein). In the trimetazidine-treated animals (32 ± 
2 ~mol/g protein at baseline) a similar pattern in the 
changes in ATP content was observed (29 ± 3, 26 ± 
3, and 27 ± 3 ~Lgmo1/g protein, at the end of the 5th 
and 15th occlusion-reperfusion sequence and after 15 
minutes of recovery, respectively). 
For both groups of animals, the total adenine nucle- 
otide levels followed the same pattern as the ATP 
levels. CP levels had increased significantly (p < 0.05) 
from 37 ± 7 ~mol/g protein at baseline to 63 ± 14 
txmol/g protein after the 5th occlusion-reperfusion cy- 
cle in the untreated animals and from 37 ± 4 ~mol/g 
protein at baseline to 62 ± 9 ~Lmo1/g protein in the 
treated animals (p < 0.05). In both groups there was 
a slight decline during the recovery period (to 54 ± 9 
txmol/g protein and 57 ± 10 ~mol/g protein in the 
untreated and treated animals at 15 minutes of reper- 
fusion, respectively). The energy charge (0.91 ± 0.09 
at baseline for both groups) was not significantly af- 
fected during the reperfusion periods. 
Myocardial malondialdehyde production 
In neither the untreated animals (0.02 ± 0.09, 0.02 
± 0.12, and 0.04 ± 0.08 nmol/mt at baseline, 2 and 
10 minutes after the last occlusion, respectively) nor 
in the trimetazidine-treated animals ( -0.02 ± 0.07, 
- 0.08 ± 0.02, and - 0.05 ± 0.08 nmol/ml at baseline, 
2 and 10 minutes after the last occlusion, respectively) 
did we observe any significant production of MDA. 
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D iscuss ion  
The model used in the present study mimicks the clini- 
cal PTCA in so far as multiple short-lasting coronary 
artery occlusions eparated by 2 minutes of reperfu- 
sions were used. In the clinical setting the effects of 
PTCA on myocardial wall motion are not well defined, 
as the duration and number of occlusions may vary 
considerably. A further complicating factor may be 
that in experimental nimals hearts are used that 
have not been submitted to myocardial ischemia be- 
fore, while in the clinical setting the myocardium has 
usually experienced several episodes of myocardial 
ischemia and may already have an abnormal wall 
motion, and possibly, metabolism because of the pres- 
ence of an existing chronic obstruction. Hence, phe- 
nomena such as ischemic preconditioning and hi- 
bernation may be confounding factors in clinical 
investigations. It is therefore not surprising that Jaski 
et al. [10] reported that after four to six balloon infla- 
tions, each lasting less than 1 minute, both systolic 
and diastolic wall motion returned to normal within 5 
minutes, while Wijns et al. [11] reported an impaired 
diastolic function in the presence of a normal systolic 
function following a similar study protocol involving a
larger number of occlusions. It therefore app~ears that 
diastolic function may be more sensitive to multiple 
short-lasting occlusions than systolic function. 
In the present study, systolic segment shortening 
completely recovered uring the first reperfusion pe- 
riod. As a matter of fact, there was even a slight in- 
crease in regional myocardial function and external 
work, which is consistent with earlier observations 
[18]. This may be, but is not necessarily [19], related 
to the hyperemic response. The aforementioned study 
[18] also showed that after such a short-lasting occlu- 
sion, stunning does not develop when perfusion is 
maintained. In the present study, myocardial stun- 
ning gradually developed uring the following occlu- 
sion-reperfusion sequences and was most pronounced 
after reperfusion was reinstated for 15 minutes. Our 
observation that regional wall function completely re- 
covered after the first occlusion, but became impaired 
during the following episodes of ischemia-reperfusion, 
appears to contradict clinical studies, which suggest, 
using electrocardiographic and metabolic abnormali- 
ties, that the first occlusion is the most damaging [20]. 
Kober et al. [9], ignoring the first occlusion, ob- 
served that electrocardiographic abnormalities were 
similar during the second and third occlusion in pa- 
tients undergoing PTCA. When trimetazidine (6rag) 
was administered intravenously before the third oc- 
clusion, the signs of ischemia were less during balloon 
inflation. Using a study protocol in which demand 
ischemia developed rather than supply ischemia, as in 
the study of Kober et al. [9], Sellier et al. [1] and 
Dalla-Volta et al. [2] also showed less evidence of isch- 
emia based on electrocardiographic abnormalities. 
The present study failed to demonstrate an effect of 
trimetazidine on recovery of function during reperfu- 
sion following repeated brief coronary artery occlu- 
sions. This does not necessarily contradict the obser- 
vation by Kober et al. [9], considering the poor 
relation between functional and electrocardiographic 
changes [21]. 
Myocardial oxygen consumption (the product of 
coronary blood flow and difference in arterial and cor- 
onary venous oxygen content) was not affected by tri- 
metazidine, which is in accordance with the concept 
that trimetazidine does not influence the hemody- 
namic variables determining myocardial oxygen de- 
mand, but it contrasts the suggestion that trimetazid- 
ine enhances the utilization of the available oxygen 
[4]. In this in vivo model, also at variance with the 
results found in isolated rat heart [4] and in isolated 
myocardial mitochondria [8], high-energy phosphates 
were not better preserved or restored in the presence 
of trimetazidine. Previously, it was shown that tri- 
metazidine can reduce ischemia-induced acidosis in 
myocardium [4]. Development of acidosis is believed 
to contribute to the deregulation ofmyocardial Ca 2+ 
homeostasis via a coupled operation of the Na+/H + 
and the Na+/Ca 2÷ exchangers [4,5]. In the present 
investigation we did not study any variable reflecting 
tissue acidosis or Ca 2+ overload, and a possible occur- 
rence of a beneficial effect of trimetazidine on tissue 
acidosis or Ca 2+ overload can therefore not be ex- 
cluded. 
MDA is one of the end products of the reaction of 
endogenously generated free radicals with membrane 
polyunsaturated fatty acids, but its formation in the 
myocardium could not be consistently demonstrated 
in the coronary effluent during the repetitive occlu- 
sion-reperfusion periods in the present study. This 
could be due to the short duration of the occlusions (2 
minutes), as we have demonstrated previously that 
MDA production occurred in anesthetized pigs that 
were subjected to 5-minute coronary artery occlusions 
[16]. On the other hand, there are two studies that 
showed trimetazidine attenuated oxygen free radical 
generation during ischemia-reperfusion [22,23]. It 
should be noted that in these studies the most convinc- 
ing evidence for free radical generation and an inhibi- 
tory effect of trimetazidine on this harmful process 
was obtained using spin-trapping agents uch as N- 
tert-butyl alpha phenylnitrone and electron paramag- 
netic resonance spectroscopy (ESR) in liquid nitrogen 
frozen myocardial biopsies. In one study the changes 
in the myocardial homogenate MDA content corre- 
sponded with the changes in ESR spectra [23]. In the 
present study, we determined MDA concentrations 
only in arterial and coronary venous blood, and no 
spin-trapping agents for detecting the earliest prod- 
ucts during oxygen free radical generation were used. 
We can therefore not make a definite statement con- 
cerning the generation of oxygen free radicals in our 
study. Nevertheless, the impairment of regional wall 
function during reperfusion, which may be a result 
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of oxygen-free radical induced damage [12], was not 
affected by trimetazidine in this particular model of 
ischemia nd reperfusion. 
The question may arise whether the lack of effect 
of trimetazidine is due to the experimental design, the 
choice of the experimental nimal, the dose or route 
of the drug, or a combination of these factors. The lack 
of any significant effect of trimetazidine on systemic 
hemodynamic variables is consistent with earlier ob- 
servations using intravenous doses. It is unlikely that 
the intracoronary dose used in this study was too low, 
considering the intravenous dose used in the study by 
Kober et al. [9]. It is also unlikely that the duration 
of the administration of trimetazidine was the cause 
for the lack of effect on regional wall function, as no 
improved recovery was seen when the duration of tri- 
metazidine administration was extended until the end 
of the 120-minute recovery period (unpublished obser- 
vations in five animals). 
In conclusion, trimetazidine in this in vivo model 
did not affect hemodynamic, metabolic, and functional 
responses to 15 repetitive short-lasting occlusions. 
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